hybridoma

(redirected from Hybridomas)
Also found in: Dictionary, Thesaurus, Medical.

hybridoma

[‚hī·brə′dō·mə]
(immunology)
A hybrid myeloma formed by fusing myeloma cells with lymphocytes that produce a specific antibody; the individual cells can be cloned, and each clone produces large amounts of identical (monoclonal) antibody.
References in periodicals archive ?
The monoclonal antibodies were purified from the pooled ascites of hybridoma cells by protein G Sepharose column chromatography.
Several inquiries have cast doubt on Table 2, where the authors present data showing that 130 of 172 hybridomas (76 percent) were secreting copycat antibodies encoded by the mouse's own genes but carrying the signature idiotype of the transgene.
Robert Ryan, Chief Executive Officer of Nuvilex, commented on the study, "The hybridoma encapsulation study directly showed the potential to address chronic sufferers of cancer, auto-immune and infectious diseases, with the ultimate goal of achieving long-term treatment from a single dose.
Antigen-specific identification and cloning of hybridomas with a fluorescence-activated cell sorter.
Kresina and his co-workers are using a common animal model of arthritis to study the effect of so-called hybridomas on the disease.
These hybridomas can be encapsulated, implanted and the antibodies they produce in the body have the potential to treat the disease.
We screened the culture supernatants of growing hybridomas for antibody activity, using rabbit anti-rat IgG-coated plates and europium-labeled EG by a procedure described previously (22).
Monoclonal antibodies are made by hybridomas, which are hybrids of antibody-producing cells and long-lived tumor cells.
As such, MabCure is capable of generating more than 10,000 hybridomas over the course of 4-6 weeks compared to classic hybridoma which generates 500-2,000 hybridomas over a period of 4-6 months.
Compared to currently available mAb technology on the market, such as mouse hybridomas, Epitomics' technology can generate antibodies more efficiently and can offer superior binding affinity and bioactivity in a wide variety of biological assays.
The protocol involving PEG and double drug selection was very effective in generating anti-PSA X anti-HRPO hybrid hybridomas.